Clinical Trials in the Netherlands / NCT06982131
Active, not recruiting
Phase 1
A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants
NCT06982131 · tracked via the Priya Life Science Netherlands tracker
Condition(s) studied
OverweightObesity
Investigational drug(s) / intervention(s)
RO7795081: RO7795081 will be administered orally during Periods 3, 4, and 5, according to the protocol.
Placebo: Placebo will be administered orally during Periods 3, 4, and 5, according to the protocol.
Rosuvastatin: A single 10 mg dose of rosuvastatin (ROS) will be taken on Day 1 of Period 1 and on Day 1 of Period 4.
Pitavastatin: A single 1 mg dose of pitavastatin (PIT) will be taken on Day 1 of Period 2 and on Day 1 of Period 5.
Study summary
This is a randomized, investigator-and-participant-blind, placebo-controlled, fixed sequence, cross-over, Phase 1 study to investigate the safety, tolerability, and pharmacokinetics of multiple doses of orally administered RO7795081 and the effect of a steady-state dose of orally administered RO7795081 on the pharmacokinetics of pitavastatin and rosuvastatin in otherwise healthy, overweight or obese adult participants.
Eligibility
Inclusion Criteria:
* Healthy participants with no clinically relevant findings on physical examination at screening and at baseline (including detailed medical and surgical history, vital signs, 12-lead ECG, hematology, blood chemistry, and urinalysis); with no suspicion of cognitive impairment or dementia as judged by the Investigator; who are not under judicial supervision, guardianship, or curatorship.
* Body Mass Index (BMI) ≥27.0 kg/m\^2 at screening and on Day -1 of Period 1
* Stable body weight (defined as \<5% gain or loss) in the 2 months prior to screening as per verbal report by the participant and for the period between screening and Day -1 of Period 1 as per measured weight
* Agreement to adhere to the contraception requirements
Exclusion Criteria:
* Pregnant, breastfeeding, or intending to become pregnant during the study
* Any condition or disease detected during the medical interview or physical examination that would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the study in the opinion of the Investigator
* History or presence of any clinically significant cardiovascular, broncho-pulmonary, hepatic, renal, gastrointestinal, endocrinological, hematological, neurological, psychiatric, or metabolic disorders, allergic diseases, hypofertility, cancer, or cirrhosis
* History or evidence of any medical condition capable of significantly altering the absorption, metabolism, or elimination of drugs
* History of convulsions (other than benign febrile convulsions of childhood) including epilepsy, or personal history of significant cerebral trauma or CNS infections (e.g., meningitis)
* History of acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma
Primary outcome measure(s)
- Incidence and Severity of Adverse Events — From the first dose of study treatment until the final visit (up to 111 days)
- Incidence of Abnormal Clinical Laboratory Test Results — From the first dose of study treatment until the final visit (up to 111 days)
- Incidence of Abnormal Vital Sign Assessments — From the first dose of study treatment until the final visit (up to 111 days)
- Incidence of Abnormal Electrocardiogram Parameters — From the first dose of study treatment until the final visit (up to 111 days)
- Maximum Plasma Concentration Observed (Cmax) of Rosuvastatin, Administered Alone and in Combination with RO7795081 — Periods 1 and 4: predose and postdose at prespecified times on Days 1 to 5
- Time to Maximum Plasma Concentration (Tmax) of Rosuvastatin, Administered Alone and in Combination with RO7795081 — Periods 1 and 4: predose and postdose at prespecified times on Days 1 to 5
- Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to the Last Measurable Concentration (AUClast) of Rosuvastatin, Administered Alone and in Combination with RO7795081 — Periods 1 and 4: predose and postdose at prespecified times on Days 1 to 5
- AUC from Time 0 to Infinity (AUCinf) of Rosuvastatin, Administered Alone and in Combination with RO7795081 — Periods 1 and 4: predose and postdose at prespecified times on Days 1 to 5
- Cmax of Pitavastatin, Administered Alone and in Combination with RO7795081 — Periods 2 and 5: predose and postdose at prespecified times on Days 1 to 4
- Tmax of Pitavastatin, Administered Alone and in Combination with RO7795081 — Periods 2 and 5: predose and postdose at prespecified times on Days 1 to 4
- AUClast of Pitavastatin, Administered Alone and in Combination with RO7795081 — Periods 2 and 5: predose and postdose at prespecified times on Days 1 to 4
- AUCinf of Pitavastatin, Administered Alone and in Combination with RO7795081 — Periods 2 and 5: predose and postdose at prespecified times on Days 1 to 4
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| ICON Plc (LPRA) - Netherlands | Groningen | Netherlands |
On this site
📄 Crestor (rosuvastatin) drug profile →More Hoffmann-La Roche trials in the Netherlands
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
Active, not recruiting
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Active, not recruiting
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Active, not recruiting
Other trials for the same condition
PET-study on the Role of the Reward System in Weight Loss After Bariatric Surgery
Active, not recruiting
010Fit'R - Healthy Lifestyle Interventions for Children With Overweight
Enrolling by invitation
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06982131 on ClinicalTrials.gov ↗ ← All trials in the Netherlands